Research Progress in Copper and Ovarian Cancer

doi:10.12280/gjfckx.20231088

Abstract

Abstract:

Ovarian cancer is one of the common gynecological malignant tumors, and most patients with ovarian cancer are discovered in their advanced stage, their prognosis and treatment effects are usually poor, which also seriously affects the quality of patients′ survival. Copper is an important trace element that participates in various important biological processes in human body and correlates closely with the progression of many malignant tumors. An increasing number of studies have explored the relationship between copper and ovarian cancer. Previous research has noticed that copper levels are apparently higher in the plasma, ascites, and tumor tissue of ovarian cancer patients than in healthy women, and the abnormal expressions of a variety of copper- transporting proteins is closely related to the resistance to platinum-based drug chemotherapy in ovarian cancer. Recently, anti-tumor therapy targeting copper metabolism has become a hot research topic. Many studies have demonstrated the significant inhibitory effect of copper chelators and ionophores on ovarian cancer in vitro and in vivo. To summarizes the close relationship between copper and ovarian cancer, and to gain a deeper understanding of the application of copper-metabolism-based drugs and therapies, which may provide new insight into the treatment of ovarian cancer.

Key words: Ovarian neoplasms, Copper, Copper transport proteins, Copper-transporting ATPases, Antineoplastic combined chemotherapy protocols, Cisplatin

ZOU Qiao-jian, YAO Shu-zhong, CHEN Yi-li, LIU Jun-xi. Research Progress in Copper and Ovarian Cancer[J]. Journal of International Obstetrics and Gynecology, 2024, 51(2): 215-219.

References 31

[1]	Ruiz LM, Libedinsky A, Elorza AA. Role of Copper on Mitochondrial Function and Metabolism[J]. Front Mol Biosci, 2021, 8:711227. doi: 10.3389/fmolb.2021.711227.
[2]	Lelièvre P, Sancey L, Coll JL, et al. The Multifaceted Roles of Copper in Cancer: A Trace Metal Element with Dysregulated Metabolism, but Also a Target or a Bullet for Therapy[J]. Cancers(Basel), 2020, 12(12):3594. doi: 10.3390/cancers12123594.
[3]	Chen J, Jiang Y, Shi H, et al. The molecular mechanisms of copper metabolism and its roles in human diseases[J]. Pflugers Arch, 2020, 472(10):1415-1429. doi: 10.1007/s00424-020-02412-2.
[4]	Lopez J, Ramchandani D, Vahdat L. Copper Depletion as a Therapeutic Strategy in Cancer[J]. Met Ions Life Sci, 2019, 19:/books/9783110527872/9783110527872-9783110527018/9783110527872-9783110527018.xml. doi: 10.1515/9783110527872-018.
[5]	Xie J, Yang Y, Gao Y, et al. Cuproptosis: mechanisms and links with cancers[J]. Mol Cancer, 2023, 22(1):46. doi: 10.1186/s12943-023-01732-y. pmid: 36882769
[6]	Denoyer D, Masaldan S, La Fontaine S, et al. Targeting copper in cancer therapy: ′Copper That Cancer′[J]. Metallomics, 2015, 7(11):1459-1476. doi: 10.1039/c5mt00149h.
[7]	Li Y. Copper homeostasis: Emerging target for cancer treatment[J]. IUBMB Life, 2020, 72(9):1900-1908. doi: 10.1002/iub.2341.
[8]	Ford CE, Werner B, Hacker NF, et al. The untapped potential of ascites in ovarian cancer research and treatment[J]. Br J Cancer, 2020, 123(1):9-16. doi: 10.1038/s41416-020-0875-x.
[9]	Onuma T, Mizutani T, Fujita Y, et al. Copper content in ascitic fluid is associated with angiogenesis and progression in ovarian cancer[J]. J Trace Elem Med Biol, 2021, 68:126865. doi: 10.1016/j.jtemb.2021.126865.
[10]	Yaman M, Kaya G, Simsek M. Comparison of trace element concentrations in cancerous and noncancerous human endometrial and ovary tissues[J]. Int J Gynecol Cancer, 2007, 17(1):220-228. doi: 10.1111/j.1525-1438.2006.00742.x. pmid: 17291257
[11]	Conforti RA, Delsouc MB, Zorychta E, et al. Copper in Gynecological Diseases[J]. Int J Mol Sci, 2023, 24(24):17578. doi: 10.3390/ijms242417578.
[12]	Toubhans B, Gourlan AT, Telouk P, et al. Cu isotope ratios are meaningful in ovarian cancer diagnosis[J]. J Trace Elem Med Biol, 2020, 62:126611. doi: 10.1016/j.jtemb.2020.126611.
[13]	Holzer AK, Manorek GH, Howell SB. Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin[J]. Mol Pharmacol, 2006, 70(4):1390-1394. doi: 10.1124/mol.106.022624. pmid: 16847145
[14]	Öhrvik H, Thiele DJ. The role of Ctr1 and Ctr2 in mammalian copper homeostasis and platinum-based chemotherapy[J]. J Trace Elem Med Biol, 2015, 31:178-182. doi: 10.1016/j.jtemb.2014.03.006. pmid: 24703712
[15]	Guo J, Sun Y, Liu G. The mechanism of copper transporters in ovarian cancer cells and the prospect of cuproptosis[J]. J Inorg Biochem, 2023, 247:112324. doi: 10.1016/j.jinorgbio.2023.112324.
[16]	Lukanović D, Herzog M, Kobal B, et al. The contribution of copper efflux transporters ATP7A and ATP7B to chemoresistance and personalized medicine in ovarian cancer[J]. Biomed Pharmacother, 2020, 129:110401. doi: 10.1016/j.biopha.2020.110401. pmid: 32570116
[17]	Samimi G, Varki NM, Wilczynski S, et al. Increase in expression of the copper transporter ATP7A during platinum drug-based treatment is associated with poor survival in ovarian cancer patients[J]. Clin Cancer Res, 2003, 9(16 Pt 1):5853-5859. pmid: 14676106
[18]	Nakayama K, Kanzaki A, Ogawa K, et al. Copper-transporting P-type adenosine triphosphatase (ATP7B) as a cisplatin based chemoresistance marker in ovarian carcinoma: comparative analysis with expression of MDR1, MRP1, MRP2, LRP and BCRP[J]. Int J Cancer, 2002, 101(5): 488-495. doi:10.1002/ijc.10608. pmid: 12216079
[19]	Yang F, Pei R, Zhang Z, et al. Copper induces oxidative stress and apoptosis through mitochondria-mediated pathway in chicken hepatocytes[J]. Toxicol In Vitro, 2019, 54:310-316. doi: 10.1016/j.tiv.2018.10.017. pmid: 30389602
[20]	Tawari PE, Wang Z, Najlah M, et al. The cytotoxic mechanisms of disulfiram and copper(ii) in cancer cells[J]. Toxicol Res(Camb), 2015, 4(6):1439-1442. doi: 10.1039/c5tx00210a.
[21]	Tsvetkov P, Coy S, Petrova B, et al. Copper induces cell death by targeting lipoylated TCA cycle proteins[J]. Science, 2022, 375(6586):1254-1261. doi: 10.1126/science.abf0529. pmid: 35298263
[22]	Chan N, Willis A, Kornhauser N, et al. Influencing the Tumor Microenvironment: A Phase Ⅱ Study of Copper Depletion Using Tetrathiomolybdate in Patients with Breast Cancer at High Risk for Recurrence and in Preclinical Models of Lung Metastases[J]. Clin Cancer Res, 2017, 23(3):666-676. doi: 10.1158/1078-0432.CCR-16-1326.
[23]	Ishida S, McCormick F, Smith-McCune K, et al. Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator[J]. Cancer Cell, 2010, 17(6):574-583. doi: 10.1016/j.ccr.2010.04.011. pmid: 20541702
[24]	Fu S, Naing A, Fu C, et al. Overcoming platinum resistance through the use of a copper-lowering agent[J]. Mol Cancer Ther, 2012, 11(6):1221-1225. doi: 10.1158/1535-7163.MCT-11-0864. pmid: 22491798
[25]	Huang YF, Kuo MT, Liu YS, et al. A Dose Escalation Study of Trientine Plus Carboplatin and Pegylated Liposomal Doxorubicin in Women With a First Relapse of Epithelial Ovarian, Tubal, and Peritoneal Cancer Within 12 Months After Platinum-Based Chemotherapy[J]. Front Oncol, 2019, 9:437. doi: 10.3389/fonc.2019.00437.
[26]	Tang X, Yan Z, Miao Y, et al. Copper in cancer: from limiting nutrient to therapeutic target[J]. Front Oncol, 2023, 13:1209156. doi: 10.3389/fonc.2023.1209156.
[27]	Guo F, Yang Z, Kulbe H, et al. Inhibitory effect on ovarian cancer ALDH+ stem-like cells by Disulfiram and Copper treatment through ALDH and ROS modulation[J]. Biomed Pharmacother, 2019, 118:109371. doi: 10.1016/j.biopha.2019.109371.
[28]	Tang B, Wu M, Zhang L, et al. Combined treatment of disulfiram with PARP inhibitors suppresses ovarian cancer[J]. Front Oncol, 2023, 13:1154073. doi: 10.3389/fonc.2023.1154073.
[29]	Du R, Sun F, Li K, et al. Proteomics Analysis Revealed Smad3 as a Potential Target of the Synergistic Antitumor Activity of Disulfiram and Cisplatin in Ovarian Cancer[J]. Anticancer Agents Med Chem, 2023, 23(15):1754-1764. doi: 10.2174/1871520623666230516161200.
[30]	Monk BJ, Kauderer JT, Moxley KM, et al. A phase Ⅱ evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study[J]. Gynecol Oncol, 2018, 151(3):422-427. doi: 10.1016/j.ygyno.2018.10.001.
[31]	Zhang J, Lu M, Xu H, et al. Molecular subtypes based on cuproptosis-related genes and tumor microenvironment infiltration characterization in ovarian cancer[J]. Cancer Cell Int, 2022, 22(1):328. doi: 10.1186/s12935-022-02756-y. pmid: 36307842